Mpox

mpox virus particles from NIAID Integrated Research Facility (credit: NIAID)
Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents
Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents
The mpox virus under a microscope
The Mpox Vaccine, MVA-BN, Receives Approval for Use in Adolescents 12 - 17 years of age
The GW VRU contributed critical data needed to approve the use of the Mpox vaccine in adolescents. This is of huge importance given the current Mpox outbreak has yet to be controlled and has disproportionately impacted children in this wave.
NIAID Image
Lower Dose of Mpox Vaccine Is Safe and Generates Six-Week Antibody Response Equivalent to Standard Regimen
Study Highlights Need for Defined Markers of Mpox Immunity to Inform Public Health Use
Subscribe to Mpox